surmount-1 tirzepatide non-diabetic obesity trial once weekly for the treatment of in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Tirzepatide Was Associated with Improved

doi: 10.1007/s00125-015-3727-0 39 XuFLinBZhengXChenZCaoHXuHet al

[63] Research continued, and in 1993, Michael Nauck managed to infuse GLP-1 into people with type 2 diabetes, stimulating insulin while inhibiting glucagon and bringing blood glucose to normal levels

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research

Clinical trials consistently show that tirzepatide outperforms single-pathway GLP-1s for weight loss

Plant Cell 17(7):18661875

Modern approaches are increasingly focused on understanding the biology behind hunger, metabolism, insulin response, and energy balance rather than relying on willpower alone